Prospective evaluation of detoxification pathways as markers of cutaneous adverse reactions to sulphonamides in AIDS

Pharmacogenetics

Volumn 10, Issue 9, 2000, Pages 821-828

  Wolkenstein, P ^a   Loriot, M A ^a   Aractingi, S ^a   Cabelguenne, A ^a   Beaune, P ^a   Chosidow, O ^a  

^a HENRI MONDOR HOSPITAL   (France)

Author keywords

Acetylation; AIDS; Glutathione S transferase; Sulphonamides

Indexed keywords

ACYLTRANSFERASE; ANTIBIOTIC AGENT; COTRIMOXAZOLE; DNA; GLUTATHIONE; GLUTATHIONE TRANSFERASE; SULFADIAZINE; SULFONAMIDE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ALLERGY; ANTIBIOTIC THERAPY; ARTICLE; DRUG HYPERSENSITIVITY; FEMALE; GENE FREQUENCY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; OPPORTUNISTIC INFECTION; PNEUMOCYSTIS PNEUMONIA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; SKIN ALLERGY; TOXOPLASMOSIS;

ACETYLATION; ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ARYLAMINE N-ACETYLTRANSFERASE; CAFFEINE; EVALUATION STUDIES; FEMALE; GENOTYPE; GLUTATHIONE TRANSFERASE; HUMANS; MALE; METABOLIC DETOXICATION, DRUG; MIDDLE AGED; PNEUMONIA, PNEUMOCYSTIS; PROSPECTIVE STUDIES; RISK FACTORS; SKIN; SULFONAMIDES; TOXOPLASMOSIS;

MARTES PENNANTI; PNEUMOCYSTIS CARINII;

EID: 0034521474     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-200012000-00007     Document Type: Article

References (39)

1. Effects of concurrent administration of other substrates of N-acetyltransferase on dapsone acetylation
2. A multiplex polymerase chain reaction protocol for the simultaneous analysis of the glutathione S-transferase GSTM1 and GSTT1 polymorphisms
3. Increased levels of oxidized glutathione In CD4+lymphocytes associated with disturbed intracellular redox balance in human immunodeficiency virus type 1 infection
4. Genotype/phenotype discordance for human arylamine N-acetyltransferase (NAT2) reveals a new slow-acetylator allele common in African-Americans
5. Human arylamine N-acetyltransferase genes: Isolation, chromosomal, localization, and functional expression
6. Allergic manifestations of human immunodeficiency virus (HIV) infections
7. In vitro cytotoxicity as a marker of hypersensitivity to sulphamethoxazole in patients with HIV
8. Acetylation phenotype and cutaneous hypersensitivity to trimethoprim-sulphamethoxazole in HIV-infected patients
9. Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: Correlation with phenotypic activity
10. Adverse cutaneous reactions to pyrimethamine/sulfadiazine and pyrimethamine/clindamycin in patients with AIDS and toxoplasmic encephalitis
11. Simultaneous characterization of glutathione S-transferase M1 and T1 polymorphisms by polymerase chain reaction in American whites and blacks
12. Reactions of the nitroso and hydroxylamine metabolites of sulfamethoxazole with reduced glutathione. Implications for idiosyncratic toxicity
13. Glutathione depletion in HIV-infected patients: Role of cysteine deficiency and effect of oral N-acetylcysteine
14. Acetylation genotype and risk of severe reactions to sulphonamides in AIDS patients
15. Glunathione S-transferase (GSTM1) null genotype and sulphonamide intolerance in acquired immunodeficiency syndrome
16. Low N-acetylating capacity in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis
17. Low concentrations of acid-soluble thiol (cysteine) in the plasma of HIV-1 infected patients
18. Prediction of phenotype for acetylation and for debrisoquine hydroxylation by DNA tests in healthy human volunteers
19. Glutathione deficiency is associated with impaired survival in HIV disease
20. N-acetyltransferase 2 polymorphism in patients infected with human immunodeficiency virus
21. Human N-acetylation genotype determination with urinary caffeine metabolites
22. Adverse reactions to trimethoprim-sulfamethoxazole
23. Altered patterns of drug metabolism in patients with acquired immunodeficiency syndrome
24. Lung cancer and mutations at the polymorphic NAT2 gene locus
25. Caffeine as a metabolic probe: NAT2 phenotyping
26. N-acetylation among HIV-positive patients and patients with AIDS: When is fast, fast and slow, slow?
27. Acetylator phenotype and genotype in patients infected with HIV: Discordance between methods for phenotype determination and genotype
28. Role of drug disposition in drug hypersensitivity: A chemical, molecular, and clinical perspective
29. Intracellular glutathione in the peripheral blood cells of HIV-infected patients: Failure to show a deficiency
30. Glutathione: Toxicological implications
31. Glutathione transferase μ deficiency is not a marker for predisposition to sulphonamide toxicity
32. Glutathione in hypersensitivity to trimethoprim/sulfamethoxazole in patients with HIV infection
33. Acetylator status and tolerance of high-dose trimethoprim-sulfamethoxazole therapy among patients infected with human immunodeficiency virus
34. Caffeine as a metabolic probe: Validation of its use for acetylator phenotyping
35. Adverse reactions to co-trimoxazole in HIV infection
36. Nomenclature for N-acetyltransferases
37. Supplementation of N-acetylcysteine fails to increase glutathione in lymphocytes and plasma of patients with AIDS
38. Slow acetylator genotype is a risk factor for sulphonamide-induced toxic epidermal necrolysis and Stevens-Johnson syndrome
39. Effect of concomitant isoniazid administration on determination of acetylator phenotype by sulphadimidine